XERS: Xeris Biopharma Holdings, Inc. Stock

by  •  • Comments Off on XERS: Xeris Biopharma Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 632.69
Enterprise Value ($M) 788.56
Book Value ($M) -29.61
Book Value / Share -0.19
Price / Book -21.21
NCAV ($M) -185.01
NCAV / Share -1.20
Price / NCAV -3.42

Profitability (mra)
Return on Invested Capital (ROIC) -0.23
Return on Assets (ROA) -0.16
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.19
Current Ratio 1.67

Balance Sheet (mrq) ($M)
Current Assets 167.66
Assets 323.06
Liabilities 352.68
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 203.07
Operating Income -33.65
Net Income -54.84
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -36.98
Cash from Investing 4.88
Cash from Financing 36.17

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 190,456 1,731,532 11.00
2025-04-16 262,546 1,761,214 14.91
2025-04-15 235,521 1,708,761 13.78
2025-04-14 241,351 1,847,955 13.06

(click for more detail)

Similar Companies
VTYX – Ventyx Biosciences, Inc. VYGR – Voyager Therapeutics, Inc.
XBIT – XBiotech Inc. XLO – Xilio Therapeutics, Inc.
YMAB – Y-mAbs Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io